The effect of Spherical Nucleic Acids on target gene expression in full thickness biopsies taken from lesional skin of volunteers with psoriasis vulgaris.
Completed
- Conditions
- psoriasis1000381610014982
- Registration Number
- NL-OMON41100
- Lead Sponsor
- Derphartox
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 3
Inclusion Criteria
Patients with psoriasis vulgaris, moderate to sever.
Exclusion Criteria
-Volunteers undergoing light therapy or taking systemic drugs such as methotrexate or cyclosporine A.
-Volunteers using local topical corticosteroids.
-Volunteers who develop psoriasis at wound sites (Köbner phenomenon).
-Volunteers with atopic dermatitis/eczematous skin conditions.
-Pregnancy
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>A decrease in skin mediator RNA levels.</p><br>
- Secondary Outcome Measures
Name Time Method <p>N/A</p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How do Spherical Nucleic Acids modulate IL-23 or TNF-α gene expression in psoriasis vulgaris lesional skin biopsies?
What is the comparative efficacy of SNA-based therapies versus standard biologics like ustekinumab in psoriasis gene regulation?
Which biomarkers correlate with SNA responsiveness in psoriasis vulgaris subtypes with distinct inflammatory profiles?
What dermatoxicity risks are associated with SNA application in full-thickness skin biopsies, and how are they managed?
How does Derphartox's SNA approach compare to other gene-targeting therapies like siRNA or antisense oligonucleotides in psoriasis?